#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bladder cancer Corneal neovascularisation Multifocal motor neuropathy Primitive neuroectodermal tumour Leukocyte adhesion deficiency Cardiomyopathy Sarcoma Malignant central nervous system neoplasm Antithrombin III deficiency Palmoplantar pustulosis Extra-osseous Ewing's sarcoma recurrent Graft versus host disease Alagille syndrome Epilepsy Systemic sclerosis pulmonary More trials…

    Learn about Rare Diseases

    Castleman’s disease Rhabdomyosarcoma Angiosarcoma non-metastatic – Basic Information Congenital generalised lipodystrophy – Trials in Disease Bronchiolitis obliterans syndrome – Basic Information Hepatic angiosarcoma – Trials in Disease Pleural mesothelioma malignant – Diagnostics Mantle cell lymphoma refractory – Trials in Disease Tuberous sclerosis complex – Trials in Disease Ornithine transcarbamoylase deficiency More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lurbinectedin Anifrolumab Magnesium Stearate Ferrous Sulfate Proline Atenolol Dacarbazine Citrate The-630 SONLICROMANOL HYDROCHLORIDE Nicotine Resinate Meropenem L-METHIONINE Cobamamide Pozelimab Emapalumab Doconexent AP31969 SULFATE Reboxetine Pasireotide Interleukin-2 More therapies…

    Learn about Your Condition

    Peripheral spondyloarthritis Herpes simplex meningitis Heart disease congenital Chronic lymphocytic leukaemia Frontotemporal dementia Autoimmune uveitis Aphthous ulcer Ewing's sarcoma metastatic Nasal sinus cancer Hypoalbuminaemia Immunosuppression Neutropenia Spermatocele Kidney transplant rejection Oesophageal adenocarcinoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cyprus

  • Efficacy and tolerability of diclofenac potassium + thiocolchicoside versus diclofenac potassium in patients with acute severe low back pain

    Recruiting

    3 1 1
    Investigated Diseases:
    • Back pain
    Investigated Drugs:
    • DICLOFENAC POTASSIUM
    • Thiocolchicoside
    • Paracetamol
    Cyprus Greece

  • A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Polyneuropathy
    Investigated Drugs:
    • Vutrisiran
    Cyprus France Germany Greece Ireland Italy +3

  • Long-Term Safety and Efficacy Study of Eplontersen in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Eplontersen
    Cyprus France Germany Italy Portugal Spain +1

  • Study of High-Dose Radiation Therapy Combined with Goserelin for High-Risk Prostate Cancer Patients Using AI-Based Treatment Planning

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Goserelin
    Cyprus

  • Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Dacarbazine
    • Doxorubicin Hydrochloride
    Cyprus Czechia Denmark France Germany Italy +4

  • Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Elacestrant
    • Anastrozole
    • Exemestane
    Belgium Cyprus France Germany Greece Ireland +5
1 2 3
Next Page

Find Clinical Trials in Your Selected Region and City

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Efgartigimod Alfa Vutrisiran Furosemide Leflunomide Mycophenolic Acid Elacestrant Duloxetine Hydroxychloroquine Sulfate Prednisolone Anastrozole Ketamine Betamethasone Tacrolimus Exemestane DICLOFENAC POTASSIUM Patisiran Letrozole Thiocolchicoside Ciclosporin Tamoxifen Paracetamol Hydrocortisone Goserelin Epirubicin Hydrochloride Azathioprine Eplontersen Dacarbazine Dexamethasone 18F-Psma-1007 Doxorubicin Hydrochloride Show more

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

Back pain Cardiac amyloidosis COVID-19 Dedifferentiated liposarcoma Drug use disorder Hereditary neuropathic amyloidosis Hormone receptor positive HER2 negative breast cancer Hormone-dependent prostate cancer Idiopathic inflammatory myopathy Leiomyosarcoma Myasthenia gravis Neoplasm Ocular myasthenia Polyneuropathy Prostate cancer

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!